Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?

Overview

Journal Can Respir J

Publisher Wiley

Specialty Pulmonary Medicine

Date 2016 Jul 23

PMID 27445541

Citations 6

Authors

C Lemaitre

S Dominique

E Billoud

M Eliezer

H Montialoux

M Quillard

G Riachi

E Koning

H Morisse-Pradier

G Savoye

C Savoye-Collet

O Goria

Affiliations

Soon will be listed here.

Abstract

Background. Cystic fibrosis-associated liver disease (CFLD) is a major cause of death. The objective of our retrospective study was to describe the relevance of magnetic resonance imaging (MRI) and liver stiffness measurement (LSM) for CFLD evaluation. Methods. All cystic fibrosis adult patients evaluated by MRI and LSM were included. MR signs of portal hypertension (PHT), dysmorphia, or cholangitis were collected and LSM expressed in kPa and Metavir. Results. Of 25 patients, 52% had abnormal MRI. Median LSM was 5.7 kPa (3.4-9.9). Three patients had F2 score and one had F3 score. In patients with PHT, LSM was 7.85 kPa (3.7-9.9) compared to 5 (3.4-7.5) in others, p = 0.02. In patients with abnormal liver function tests, 50% had increased LSM (≥F2), whereas 94% with normal tests had normal LSM (p = 0.04). Seven patients had abnormal MRI despite normal ultrasonography. Conclusions. MRI and LSM provide useful information on CFLD and may help to screen patients with PHT.

Citing Articles

Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.

Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M Hepatology. 2023; 79(5):1220-1238.

PMID: 37934656 PMC: 11020118. DOI: 10.1097/HEP.0000000000000646.

Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound.

Towbin A, Ye W, Huang S, Karmazyn B, Molleston J, Masand P Pediatr Radiol. 2023; 53(11):2210-2220.

PMID: 37500799 DOI: 10.1007/s00247-023-05706-6.

Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Hercun J, Alvarez F, Vincent C, Bilodeau M Can Liver J. 2022; 2(3):71-83.

PMID: 35990223 PMC: 9202747. DOI: 10.3138/canlivj-2018-0019.

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N Eur Radiol. 2018; 29(2):1048-1058.

PMID: 30054796 PMC: 6302923. DOI: 10.1007/s00330-018-5650-5.

Limitations and opportunities of non-invasive liver stiffness measurement in children.

Engelmann G, Quader J, Teufel U, Schenk J World J Hepatol. 2017; 9(8):409-417.

PMID: 28357028 PMC: 5355763. DOI: 10.4254/wjh.v9.i8.409.

References

Smith J, Lewindon P, Hoskins A, Pereira T, Setchell K, OConnell N . Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology. 2004; 39(6):1673-82. DOI: 10.1002/hep.20238. View

Witters P, Libbrecht L, Roskams T, De Boeck K, Dupont L, Proesmans M . Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology. 2011; 53(3):1064-5. DOI: 10.1002/hep.24183. View

Corpechot C, Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O . Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology. 2006; 43(5):1118-24. DOI: 10.1002/hep.21151. View

Soto J, Barish M, Yucel E, Siegenberg D, Ferrucci J, Chuttani R . Magnetic resonance cholangiography: comparison with endoscopic retrograde cholangiopancreatography. Gastroenterology. 1996; 110(2):589-97. DOI: 10.1053/gast.1996.v110.pm8566608. View

Wanless I . Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology. 1990; 11(5):787-97. DOI: 10.1002/hep.1840110512. View

Kinnman N, Lindblad A, Housset C, Buentke E, Scheynius A, Strandvik B . Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology. 2000; 32(2):334-40. DOI: 10.1053/jhep.2000.9111. View

Sediva A, Bartunkova J, Bartosova J, Jennette C, Falk R, Jethwa H . Antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein detected in children with cystic fibrosis inhibit neutrophil-mediated killing of Pseudomonas aeruginosa. Microbes Infect. 2003; 5(1):27-30. DOI: 10.1016/s1286-4579(02)00049-7. View

Hillaire S, Bonte E, Denninger M, Casadevall N, Cadranel J, Lebrec D . Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002; 51(2):275-80. PMC: 1773310. DOI: 10.1136/gut.51.2.275. View

Colombo C, Battezzati P, Podda M, Bettinardi N, Giunta A . Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology. 1996; 23(6):1484-90. DOI: 10.1002/hep.510230627. View

10.

Ramm G, Shepherd R, Hoskins A, Greco S, Ney A, Pereira T . Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology. 2008; 49(2):533-44. DOI: 10.1002/hep.22637. View

11.

Colombo C, Russo M, Zazzeron L, Romano G . Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2006; 43 Suppl 1:S49-55. DOI: 10.1097/01.mpg.0000226390.02355.52. View

12.

Robertson M, Choe K, Joseph P . Review of the abdominal manifestations of cystic fibrosis in the adult patient. Radiographics. 2006; 26(3):679-90. DOI: 10.1148/rg.263055101. View

13.

OSullivan B, Linden M, Frelinger 3rd A, Barnard M, Spencer-Manzon M, Morris J . Platelet activation in cystic fibrosis. Blood. 2005; 105(12):4635-41. DOI: 10.1182/blood-2004-06-2098. View

14.

Abraham S, Kamath P, Eghtesad B, Demetris A, Krasinskas A . Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol. 2006; 30(11):1454-61. DOI: 10.1097/01.pas.0000213286.65907.ea. View

15.

Cheng K, Ashby D, Smyth R . Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2000; (2):CD000222. DOI: 10.1002/14651858.CD000222. View

16.

Colombo C, Battezzati P, Crosignani A, Morabito A, Costantini D, Padoan R . Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome. Hepatology. 2002; 36(6):1374-82. DOI: 10.1053/jhep.2002.37136. View

17.

Navasa M, Pares A, Bruguera M, Caballeria J, Bosch J, Rodes J . Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol. 1987; 5(3):292-8. DOI: 10.1016/s0168-8278(87)80035-1. View

18.

Durieu I, Pellet O, Simonot L, Durupt S, Bellon G, Durand D . Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol. 1999; 30(6):1052-6. DOI: 10.1016/s0168-8278(99)80259-1. View

19.

Sokol R, Durie P . Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999; 28 Suppl 1:S1-13. DOI: 10.1097/00005176-199900001-00001. View

20.

Roskams T, Baptista A, Bianchi L, Burt A, Callea F, Denk H . Histopathology of portal hypertension: a practical guideline. Histopathology. 2002; 42(1):2-13. DOI: 10.1046/j.1365-2559.2003.01464.x. View